Annual Accounts Payable
$27.51 M
-$5.61 M-16.95%
December 31, 2024
Summary
- As of March 3, 2025, IOVA annual accounts payable is $27.51 million, with the most recent change of -$5.61 million (-16.95%) on December 31, 2024.
- During the last 3 years, IOVA annual accounts payable has risen by +$132.00 thousand (+0.48%).
- IOVA annual accounts payable is now -16.95% below its all-time high of $33.12 million, reached on December 31, 2023.
Performance
IOVA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$27.51 M
-$4.18 M-13.18%
December 31, 2024
Summary
- As of March 3, 2025, IOVA quarterly accounts payable is $27.51 million, with the most recent change of -$4.18 million (-13.18%) on December 31, 2024.
- Over the past year, IOVA quarterly accounts payable has stayed the same.
- IOVA quarterly accounts payable is now -16.95% below its all-time high of $33.12 million, reached on December 31, 2023.
Performance
IOVA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
IOVA Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -16.9% | 0.0% |
| 3 y3 years | +0.5% | 0.0% |
| 5 y5 years | +76.7% | 0.0% |
IOVA Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -16.9% | +3.4% | -16.9% | +42.7% |
| 5 y | 5-year | -16.9% | +103.6% | -16.9% | +168.7% |
| alltime | all time | -16.9% | -100.0% | -16.9% | -100.0% |
Iovance Biotherapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $27.51 M(-16.9%) | $27.51 M(-13.2%) |
| Sep 2024 | - | $31.69 M(+55.2%) |
| Jun 2024 | - | $20.42 M(-20.6%) |
| Mar 2024 | - | $25.70 M(-22.4%) |
| Dec 2023 | $33.12 M(+24.5%) | $33.12 M(+71.9%) |
| Sep 2023 | - | $19.27 M(-38.1%) |
| Jun 2023 | - | $31.16 M(-1.3%) |
| Mar 2023 | - | $31.57 M(+18.7%) |
| Dec 2022 | $26.60 M(-2.8%) | $26.60 M(+9.7%) |
| Sep 2022 | - | $24.25 M(+21.2%) |
| Jun 2022 | - | $20.01 M(-2.2%) |
| Mar 2022 | - | $20.45 M(-25.3%) |
| Dec 2021 | $27.38 M(+102.6%) | $27.38 M(+124.8%) |
| Sep 2021 | - | $12.18 M(-44.4%) |
| Jun 2021 | - | $21.91 M(+63.9%) |
| Mar 2021 | - | $13.37 M(-1.1%) |
| Dec 2020 | $13.51 M(-13.2%) | $13.51 M(-45.5%) |
| Sep 2020 | - | $24.79 M(+142.2%) |
| Jun 2020 | - | $10.24 M(-3.5%) |
| Mar 2020 | - | $10.61 M(-31.8%) |
| Dec 2019 | $15.57 M(+468.3%) | $15.57 M(+56.9%) |
| Sep 2019 | - | $9.92 M(-22.4%) |
| Jun 2019 | - | $12.78 M(+68.4%) |
| Mar 2019 | - | $7.59 M(+177.1%) |
| Dec 2018 | $2.74 M(+122.3%) | $2.74 M(-54.5%) |
| Sep 2018 | - | $6.01 M(+15.7%) |
| Jun 2018 | - | $5.20 M(-21.0%) |
| Mar 2018 | - | $6.58 M(+433.8%) |
| Dec 2017 | $1.23 M | $1.23 M(-57.6%) |
| Sep 2017 | - | $2.90 M(-21.4%) |
| Jun 2017 | - | $3.69 M(+70.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $2.17 M(+151.9%) |
| Dec 2016 | $863.00 K(-9.9%) | $863.00 K(+278.5%) |
| Sep 2016 | - | $228.00 K(-68.6%) |
| Jun 2016 | - | $725.00 K(-31.2%) |
| Mar 2016 | - | $1.05 M(+10.0%) |
| Dec 2015 | $958.00 K(-23.2%) | $958.00 K(-17.5%) |
| Sep 2015 | - | $1.16 M(+0.4%) |
| Jun 2015 | - | $1.16 M(+4.5%) |
| Mar 2015 | - | $1.11 M(-11.3%) |
| Dec 2014 | $1.25 M(+202.2%) | $1.25 M(+117.5%) |
| Sep 2014 | - | $573.80 K(+30.3%) |
| Jun 2014 | - | $440.50 K(+53.9%) |
| Mar 2014 | - | $286.30 K(-30.7%) |
| Dec 2013 | $413.00 K(-62.4%) | $413.00 K(-73.4%) |
| Sep 2013 | - | $1.55 M(+4.7%) |
| Jun 2013 | - | $1.48 M(+14.6%) |
| Mar 2013 | - | $1.29 M(+17.6%) |
| Dec 2012 | $1.10 M(+478.1%) | $1.10 M(+30.5%) |
| Sep 2012 | - | $841.60 K(+38.1%) |
| Jun 2012 | - | $609.30 K(+20.8%) |
| Mar 2012 | - | $504.30 K(+165.4%) |
| Dec 2011 | $190.00 K(+527.1%) | $190.00 K(-8.2%) |
| Sep 2011 | - | $206.90 K(+58.4%) |
| Jun 2011 | - | $130.60 K(+80.1%) |
| Mar 2011 | - | $72.50 K(+139.3%) |
| Dec 2010 | $30.30 K(>+9900.0%) | $30.30 K(+18.8%) |
| Sep 2010 | - | $25.50 K(+61.4%) |
| Jun 2010 | - | $15.80 K(-7.6%) |
| Mar 2010 | - | $17.10 K(>+9900.0%) |
| Dec 2009 | $0.00 | $0.00(-100.0%) |
| Jun 2009 | - | $3800.00 |
FAQ
- What is Iovance Biotherapeutics annual accounts payable?
- What is the all time high annual accounts payable for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual accounts payable year-on-year change?
- What is Iovance Biotherapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly accounts payable year-on-year change?
What is Iovance Biotherapeutics annual accounts payable?
The current annual accounts payable of IOVA is $27.51 M
What is the all time high annual accounts payable for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual accounts payable is $33.12 M
What is Iovance Biotherapeutics annual accounts payable year-on-year change?
Over the past year, IOVA annual accounts payable has changed by -$5.61 M (-16.95%)
What is Iovance Biotherapeutics quarterly accounts payable?
The current quarterly accounts payable of IOVA is $27.51 M
What is the all time high quarterly accounts payable for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly accounts payable is $33.12 M
What is Iovance Biotherapeutics quarterly accounts payable year-on-year change?
Over the past year, IOVA quarterly accounts payable has changed by $0.00 (0.00%)